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ABSTRACT
Introduction: Cyclooxygenase 2 (COX-2) inhibitors
have less upper gastrointestinal toxicity than traditional
non-steroidal anti-inflammatory drugs (NSAIDs).
However, both COX-2 inhibitors and traditional NSAIDs
may be associated with adverse cardiovascular side
effects. Data from randomised and observational studies
suggest that celecoxib has similar cardiovascular
toxicity to traditional NSAIDs. The overall safety balance
of a strategy of celecoxib therapy versus traditional
NSAID therapy is unknown. The European Medicines
Agency requested studies of the cardiovascular safety
of celecoxib within Europe. The Standard care versus
Celecoxib Outcome Trial (SCOT) compares the
cardiovascular safety of celecoxib with traditional NSAID
therapy in the setting of the European Union healthcare
system.
Methods and analysis: SCOT is a large streamlined
safety study conducted in Scotland, England, Denmark
and the Netherlands using the Prospective Randomised
Open Blinded Endpoint design. Patients aged over
60 years with osteoarthritis or rheumatoid arthritis, free
from established cardiovascular disease and requiring
chronic NSAID therapy, are randomised to celecoxib or
their previous traditional NSAID. They are then followed
up for events by record-linkage within their normal
healthcare setting. The hypothesis is non-inferiority with
a confidence limit of 1.4. The primary endpoint is the
first occurrence of hospitalisation or death for the Anti-
Platelet Trialists’ Collaboration (APTC) cardiovascular
endpoint of non-fatal myocardial infarction, non-fatal
stroke or cardiovascular death. Secondary endpoints are
(1) first hospitalisation or death for upper
gastrointestinal ulcer complications (bleeding,
perforation or obstruction); (2) first occurrence of
hospitalised upper gastrointestinal ulcer complications
or APTC endpoint; (3) first hospitalisation for heart
failure; (4) first hospitalisation for APTC endpoint plus
heart failure; (5) all-cause mortality and (6) first
hospitalisation for new or worsening renal failure.
Ethics and dissemination: SCOT has been approved
by the relevant ethics committees. The trial results will
be published in a peer-reviewed scientific journal.
Clinical trials registration number: Clinicaltrials.
gov (NCT00447759).
ARTICLE SUMMARY
Article focus
▪ The Standard care versus Celecoxib Outcome Trial
(SCOT) compares the cardiovascular and gastro-
intestinal safety of a strategy of celecoxib therapy
and a strategy of traditional non-steroidal anti-
inflammatory drug (NSAID) therapy in patients with
osteoarthritis or rheumatoid arthritis aged over
60 years without a history of cardiovascular disease.
Key messages
▪ SCOT is a prospective randomised trial compar-
ing celecoxib with traditional NSAIDs in patients
with arthritis without a history of cardiovascular
disease.
▪ The cardiovascular safety of NSAIDs is an
important issue where more evidence is required
to guide practice.
▪ SCOT uses electronic record-linkage to collect
data on endpoints.
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INTRODUCTION
Non-steroidal anti-inﬂammatory drug (NSAID)-induced
gastrointestinal toxicity is one of the most common
serious drug adverse events requiring hospitalisation.1
Upper gastrointestinal complications result in consider-
able morbidity and mortality. The cyclooxygenase 2
(COX-2) selective NSAIDs gained popularity based on
evidence that they are associated with a lower incidence
of ulcer-related upper gastrointestinal tract complica-
tions compared with traditional non-selective NSAID
therapy. However, the withdrawal of rofecoxib2 due to
cardiovascular toxicity and the suggestion that most
NSAIDs are probably associated with increased cardiovas-
cular adverse events when compared with placebo3 have
led to the need for further prospective studies on the
safety of other COX-2 inhibitors and traditional NSAIDs.
The cardiovascular safety proﬁle of COX-2 inhibitors
was brought into question following the results of two
placebo-controlled studies designed to test the hypoth-
esis that the COX-2 inhibitors rofecoxib and celecoxib
might prevent colorectal adenomas and colorectal
tumours. The Adenomatous Polyp Prevention on Vioxx
Trial randomised patients with a history of colorectal
adenomas to rofecoxib 25 mg or placebo and reported
an excess of cardiovascular thrombotic events in the
group treated with rofecoxib.4 The Prevention of
Sporadic Colorectal Adenomas with Celecoxib (APC)
Trial randomised patients with previous colorectal aden-
omas to celecoxib 400 mg twice daily, celecoxib 200 mg
twice daily or placebo and reported a dose-related
increase in the risk of cardiovascular events in the cele-
coxib groups.5 6 However, the Prevention of Colorectal
Sporadic Adenomatous Polyps (PreSAP) Trial did not
show a signiﬁcant increase in cardiovascular events with
celecoxib 400 mg given once per day versus placebo in
patients with previous colorectal adenomas.7 In the
Alzheimer’s Disease Anti-Inﬂammatory Prevention Trial
(ADAPT), which was stopped early due to the ﬁndings
of the APC trial, there was a suggestion of an increased
risk of cardiovascular events with naproxen but not cele-
coxib compared with placebo, although this study was
underpowered, and the cardiovascular results must
therefore be interpreted with caution. In a later
meta-analysis of six randomised double-blind placebo
controlled trials of celecoxib in non-arthritis conditions,
which included analysis of the APC, PreSAP and ADAPT
studies and three other smaller studies (MA27, The
Diabetic Macular Edema Trial and the Celecoxib/
Selenium Trial), there was no evidence of increased car-
diovascular risk with celecoxib in low-risk patients but
there was a dose-dependent increase in cardiovascular
risk in high-risk patients.8
In the Multinational Etoricoxib and Diclofenac
Arthritis Long-term programme, which compared car-
diovascular outcomes with etoricoxib 60 or 90 mg daily
and diclofenac 150 mg daily in patients with osteoarth-
ritis or rheumatoid arthritis, the rates of thrombotic car-
diovascular events were similar in patients randomised
to either drug.9
In trials of celecoxib versus traditional NSAIDs, no evi-
dence of increased cardiovascular toxicity has been
seen.10 In large observational studies, celecoxib has not
been found to be associated with increased cardiovascu-
lar risk versus other NSAIDs11 or non-use.12 13 At
present, much of the available data comes from observa-
tional studies and while it seems clear that rofecoxib
increased cardiovascular risk, many traditional NSAIDs
may also pose considerable risk.3 11 14–16
The recent Celecoxib versus Omeprazole and
Diclofenac in patients with Osteoarthritis and Rheumatoid
arthritis study found that celecoxib was associated with a
lower incidence of clinically signiﬁcant upper or lower
gastrointestinal events than the combination of diclofenac
and omeprazole, adding further evidence to the improved
gastrointestinal safety of COX-2 inhibitors compared with
non-selective NSAIDs.17
Against this background of conﬂicting data, the overall
risk-beneﬁt balance of celecoxib versus traditional NSAIDs
needs to be better clariﬁed in a prospective trial design.
This paper describes the design and rationale for The
Standard care versus Celecoxib Outcome Trial (SCOT),
which is a prospective trial randomising patients without a
history of cardiovascular disease to celecoxib or traditional
NSAID and measuring cardiovascular outcomes that is
expected to report in 2014. This trial, which started
recruiting in 2008, is a large streamlined safety study of cel-
ecoxib versus traditional NSAIDs in patients with osteo-
arthritis or rheumatoid arthritis that aims to address the
relative cardiovascular and gastrointestinal safety of the
two treatment strategies in a real-world setting.
METHODS AND ANALYSIS
Trial design
Overall trial design
SCOT is an active comparator, streamlined clinical trial
with a Prospective, Randomised, Open label, Blinded
Endpoint evaluation (PROBE) design.18 It aims to
compare the cardiovascular and gastrointestinal safety of
continuing with current traditional NSAID therapy
ARTICLE SUMMARY
Strengths and limitations of this study
▪ SCOT is a prospective randomised trial in a population of
patients who take NSAIDs in the long term and are, therefore,
representative of patients who might be at risk from NSAID
therapy. SCOT is a streamlined safety trial with good external
validity as it is conducted in the normal care setting. The limita-
tions of the study include the need to extrapolate from the
results to guide therapy in younger patients and in patients
without a history of using NSAIDS and the lack of traditional
study follow-up visits, although it has been shown that
record-linkage can be used effectively in trial follow-up to
detect events.
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versus switching to celecoxib therapy in patients with
osteoarthritis or rheumatoid arthritis. After randomisa-
tion to celecoxib or continuation of their current trad-
itional NSAID therapy, subjects are followed up for an
average of 2 years for predeﬁned cardiovascular, gastro-
intestinal and renal events and mortality (ﬁgure 1).
Study population
The European Medicines Agency requested that the
trial population should include patients from at least
two European Member States. The trial is being con-
ducted in the UK, Denmark and the Netherlands.
Patients over the age of 60 years, who are free from car-
diovascular disease and are taking chronic NSAID
therapy for osteoarthritis or rheumatoid arthritis, are
included in the study. The trial inclusion and exclusion
criteria are listed in boxes 1 and 2, respectively.
Recruitment and randomisation of participants
Potentially suitable patients are identiﬁed from general
practice populations. Written informed consent is
obtained from participants. The research nurse records
baseline variables, takes blood and urine for baseline
biochemistry and haematology and records the medical
history. Blood samples are analysed at the local health
service laboratory according to usual practice. Serum for
future analyses and blood for future genetic analyses are
stored by regional centres. Subjects who have given
informed consent and meet the inclusion and exclusion
criteria are randomised to receive celecoxib or to con-
tinue on their usual traditional NSAID therapy.
Randomisation is performed by contacting a central ran-
domisation facility based at the Robertson Centre for
Biostatistics, University of Glasgow by telephone or via a
web-based service.
Stratification of randomisation
Prior to the start of the study, a group of general practi-
tioners’ databases in Scotland and the centralised dis-
pensing database in Denmark were screened to identify
the distribution of usage of different NSAIDs. On this
basis, each NSAID with a frequency of usage >12% (ibu-
profen and diclofenac) was assigned its own stratum.
Other NSAIDs were pooled into a single stratum for the
Figure 1 Current Standard care
versus Celecoxib Outcome Trial
design.
Box 1 Inclusion criteria
1. Age 60 or over.
2. Male and female subjects.
3. Chronic non-steroidal anti-inflammatory drug (NSAID) use
(≥90 days or at least three filled prescriptions in the last year).
4. Subjects who, in the opinion of the recruiting physician, have
a licensed indication for chronic non-selective NSAID or cele-
coxib therapy (osteoarthritis or rheumatoid arthritis).
5. Subjects who, in the opinion of the study site coordinator, are
eligible for treatment (with reference to the summary of
product characteristics) with either celecoxib or an alternative
traditional non-selective NSAID. In particular, these subjects
must be free from established cardiovascular disease (estab-
lished ischaemic heart disease (IHD), heart failure, cerebrovas-
cular disease and peripheral arterial disease).
6. Subjects who are willing to give permission for their paper
and electronic medical records and prescribing data to be
accessed and abstracted by trial investigators.
7. Subjects who are willing to be contacted and interviewed by
trial investigators, should the need arise for adverse event
assessment, etc.
8. For the avoidance of doubt, there are no other specific
comorbidities or concurrent drug therapies (including aspirin)
that are contraindicated.
Box 2 Exclusion criteria
1. Established cardiovascular disease including IHD such as
myocardial infarction, angina or acute coronary syndrome,
cerebrovascular disease such as a cerebrovascular accident
or transient ischaemic attack, established peripheral vascular
disease and moderate or severe heart failure.
2. Subject currently taking a COX-2 selective NSAID (celecoxib
or etoricoxib), or having received one of the therapies within
90 days of screening.
3. Presence of a life-threatening comorbidity (investigator
opinion).
4. Presence of clinically important renal or hepatic disease
(investigator opinion).
5. Subjects whose behaviour or lifestyle would render them
less likely to comply with study medication (ie, alcoholism,
substance misuse, debilitating psychiatric conditions or
inability to provide informed consent).
6. Subjects with known or suspected allergy to celecoxib or
NSAIDs including aspirin.
7. Subjects with known hypersensitivity to sulfonamide
antibiotics.
8. Subjects with active peptic ulceration or gastrointestinal (GI)
bleeding.
9. Subjects scheduled to have arthritis surgery likely to modify
their need for pain relief within the next year.
10. Subjects currently participating in another clinical trial or
who have been in a trial in the previous 3 months.
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purpose of randomisation. The allocated therapy is pre-
scribed using the normal health service prescription
form. Thus, therapy is provided to patients in an open-
label fashion in order to mimic normal care as closely as
possible.
After randomisation, a health service prescription is
issued for the randomised drug and the patient’s case
records and computer ﬁle are marked to show that they
are participating in SCOT. Repeat prescriptions are
issued according to normal clinical practice and patients
take their medication according to clinical need. This
method is ‘naturalistic’ in that it most closely mimics the
real world of NSAID use.
Trial treatments
The trial treatments are either celecoxib (Celebrex) or any
other licensed, non-selective traditional NSAID listed in the
British National Formulary section 10.1.1 (ibuprofen, ace-
clofenac, acemetacin, dexibuprofen, dexketoprofen, diclo-
fenac sodium, diﬂunisal, etodolac, fenbufen, fenoprofen,
ﬂurbiprofen, ibuprofen, indometacin, ketoprofen, mefe-
namic acid, meloxicam, nabumetone, naproxen, piroxi-
cam, sulindac, tenoxicam, tiaprofenic acid and Arthrotec
(diclofenac plus misoprostol)).
Celecoxib is prescribed at standard licensed doses of
up to 200 mg twice daily—the dose is adjusted as neces-
sary up to this maximum limit to provide adequate
symptomatic relief. Other NSAIDs are continued at their
standard licensed doses and again, the dose may be
adjusted as necessary to control symptoms.
Compliance
Study medication prescriptions are recorded on practice
computer systems. Compliance is measured as the number
of prescription doses prescribed divided by the number of
days between prescriptions averaged over the time in the
trial.
Discontinuation of randomised therapy
If a period of 56 days elapses from the estimated end of
the last written prescription or if a prescription is written
for a traditional NSAID or COX-2 inhibitor other than
that allocated at the time of randomisation, it is con-
ﬁrmed whether the patient has discontinued therapy
and, if appropriate, the reason for study drug discon-
tinuation is recorded.
Concomitant medications
Concomitant medications are also recorded. Of particu-
lar interest are prescriptions for aspirin, ulcer healing
drugs and antihypertensive drugs.
Rescue medication
Efficacy
Patients who experience the onset of inadequate thera-
peutic efﬁcacy may be up-titrated in dose as per normal
clinical practice. Such dose escalations are tracked.
Additional rescue medication may be prescribed in order
that the patient continues on randomised therapy. These
rescue medications may include paracetamol (acetamino-
phen), opiates such as codeine, dihydrocodeine, tramadol,
etc, nefopam, low dose antidepressant therapy and other
recognised analgesic augmenting therapies.
Tolerability
Patients who experience the onset of symptoms of upper
gastrointestinal discomfort, dyspepsia or heartburn may
be prescribed antacid therapy or ulcer healing therapy
at the discretion of their primary care physician. Study
site coordinators report such events as treatment-related
adverse events and specify if they lead to discontinuation
of randomised study treatment.
Original study design with a celecoxib run-in period
(2008–2010 prior to protocol amendment)
In the original trial design (for patients entering the
study up to between April and August 2010 depending
on the study site), 3962 subjects underwent a celecoxib
run-in period prior to randomisation and 2545 subjects
were subsequently randomised. The celecoxib run-in
was carried out in all patients completing screening for
the study. They were asked to discontinue their current
NSAID and enter a 2-week (14±7 days) open-label run-in
of treatment with celecoxib as two to four 100 mg tablets
taken daily in single or divided doses (ﬁgure 2). During
the run-in period, the dose of celecoxib was titrated to
achieve equivalent pain control to their previous NSAID
therapy. At the end of this period, subjects who had
taken at least one dose of celecoxib and who did not
express a strong preference for either their previous
treatment or celecoxib were eligible for randomisation.
Preference was determined by the patient response to a
questionnaire:
Which statement do you agree with?
1. My previous painkiller was much better than
celecoxib
2. My previous painkiller was somewhat better than
celecoxib
3. My previous painkiller and celecoxib were the same
4. Celecoxib was somewhat better than my previous
painkiller
5. Celecoxib was much better than my previous
painkiller
Only subjects who responded with answers 2, 3 or 4
were eligible for randomisation. This resulted in 1417
subjects being excluded using this run-in period.
This open-label celecoxib run-in period was originally
included in the design of SCOT because a major
problem with previous randomised trials of NSAID tox-
icity had been dropout from randomised treatment
during the trial. For example, in the Therapeutic
Arthritis Research and Gastrointestinal Event Trial, only
60% of subjects completed the trial and 31–37% of
subjects withdrew from randomised therapy.19 In the
CLASS study, less than 50% of those randomised com-
pleted the study and there was differential dropout
4 MacDonald TM, Mackenzie IS, Wei L, et al. BMJ Open 2013;3:e002295. doi:10.1136/bmjopen-2012-002295
Standard care versus Celecoxib Outcome Trial (SCOT) protocol
 group.bmj.com on April 4, 2013 - Published by bmjopen.bmj.comDownloaded from 
between the two treatment arms.20 A similar trial run-in
phase was used in the Heart Protection Study.21 It was
hoped that by having a celecoxib run-in period, drop-
outs after randomisation would be avoided. However,
after a review of the data on the level of dropouts after
the ﬁrst few years of the trial, it was clear that the cele-
coxib run-in period was resulting in different rates of
randomisation in different centres with hardly any being
excluded in some centres and a high proportion being
excluded in others. For this reason, the protocol was
amended to remove the run-in period and to perform
randomisation on the day of screening if the subject was
eligible. This amendment was implemented in each
region on different dates but was completed by
September 2010. Since then, up to October 2012,
around 3500 further patients were randomised without a
run-in period. We have since formally evaluated the
inﬂuence of the presence or absence of the celecoxib
run-in period on study dropout rates and found no sig-
niﬁcant difference (adjusted OR for dropout at 180 days
in patients with the celecoxib run-in period was 1.28
(95% CI 0.76 to 2.14).22
Trial endpoints
Primary endpoint
The primary endpoint is the ﬁrst occurrence of hospitalisa-
tion or death for the Anti-Platelet Trialists’ Collaboration
cardiovascular endpoint of non-fatal myocardial infarction,
non-fatal stroke or cardiovascular death.
The secondary and tertiary endpoints and further
planned analyses are listed in box 3.
Assessment of study endpoints, adverse events
and serious adverse events
The principal mode of collection of study endpoints,
adverse events and serious adverse events (SAEs) in
SCOT is by record-linkage from national population
healthcare databases. Record-linkage retrieves electronic
records of hospitalisations and deaths for individual
patients within the study from central databases.
Hospitalisation discharge diagnoses are coded and
causes of death are reported. Any events of particular
interest (potential study endpoints) are investigated
further and conﬁrmed by retrieving the original case
records. Record-linkage has previously been demon-
strated to be highly effective in the follow-up of patients
for study events.23 Any treatment-related adverse events
and SAEs detected and reported by research staff or
physicians manually are also collected and investigated.
Box 3 Secondary and tertiary endpoints and further
analyses
Secondary endpoints
1. First occurrence of hospitalisation or death for upper gastro-
intestinal ulcer complications (bleeding, perforation or
obstruction).
2. First occurrence of hospitalised upper gastrointestinal ulcer
complications or Anti-Platelet Trialists’ Collaboration (APTC)
endpoint.
3. First hospitalisation for heart failure.
4. First occurrence of hospitalisation for APTC endpoint plus
heart failure.
5. All cause mortality.
6. First hospitalisation for new or worsening renal failure.
Tertiary endpoints
1. First occurrence of hospitalisation or death for upper gastro-
intestinal bleeding, perforation or obstruction not due to
ulcers.
2. First occurrence of hospitalisation or death for lower gastro-
intestinal bleeding, perforation or obstruction.
3. First occurrence of hospitalisation or death for all episodes of
gastrointestinal bleeding, perforation or obstruction.
Further planned analyses
1. Myocardial infarction as a whole and as the components of
ST segment elevation myocardial infarction and non ST eleva-
tion myocardial infarction.
2. Non-fatal stroke.
3. Cardiovascular death.
4. Analyses of GI subcomponents
A. Hospitalisation or death for all episodes of upper
gastrointestinal bleeding;
B. Hospitalisation or death for all episodes of lower
gastrointestinal bleeding and
C. Hospitalisation or death for all episodes of gastrointes-
tinal bleeding.
5. All uncomplicated upper gastrointestinal ulcers detected
during the study.
6. All upper gastrointestinal ulcers (complicated and uncompli-
cated) detected during the study.
7. New prescription for ulcer healing drugs.
8. All hospitalisations.
Figure 2 Original Standard care
versus Celecoxib Outcome Trial
design (including 2-week
celecoxib run-in period).
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Mortality data by record-linkage
Mortality and certiﬁed cause-speciﬁc mortality are
retrieved from national mortality record systems by
record-linkage at approximately 3 monthly intervals.
Morbidity data by record-linkage
Hospitalisations are retrieved by record-linkage from
national systems at approximately 3 monthly intervals.
Data abstraction for endpoint adjudication
For each death, and for each hospitalisation that is a
potential endpoint, primary care and secondary care
records and, if appropriate, full death certiﬁcation data
are retrieved. Diagnostic validation forms are ﬁlled in to
supplement scanned images of original case records
relating to the endpoints in question. The scanned
images of case records and the data validation forms are
collated. Any record of randomised treatment is
removed before these collated documents are passed to
the relevant (cardiovascular or gastrointestinal) end-
point committee for adjudication as to the hospital diag-
nosis or the cause of death. This is the PROBE design,
which is similar to the design of the Anglo Scandinavian
Cardiac Outcomes Trial.24
Adjudication of endpoints
Endpoint data are adjudicated by two independent end-
point committees, one for cardiovascular endpoints
(also adjudicated in heart failure, renal and death end-
points) and one for gastrointestinal endpoints. These
committees are blinded to randomised treatment and
have due regard of the published consensus diagnostic
criteria for myocardial infarction,25 stroke,26 vascular
death, ulcer-related upper gastrointestinal hospitalisa-
tions or death, heart failure27 and renal failure.28 29
Adverse events
All observed or volunteered adverse events that are con-
sidered to be serious or related to randomised study
treatment, regardless of the treatment group or sus-
pected causal relationship to the investigational product
(s), are recorded on the adverse event pages of the elec-
tronic case report form. Adverse events are deﬁned as
abnormal test ﬁndings, clinically signiﬁcant symptoms
and signs, changes in physical examination ﬁndings or
hypersensitivity. An SAE or a serious adverse drug reac-
tion is any untoward medical occurrence at any dose
that: results in death, is life-threatening (immediate risk
of death), requires inpatient hospitalisation or prolonga-
tion of existing hospitalisation, results in persistent or
signiﬁcant disability/incapacity or results in a congenital
anomaly or birth defect.
For these adverse events, further information is
obtained to determine the outcome of the adverse event
and to conﬁrm whether it meets the criteria for classiﬁ-
cation as an SAE requiring immediate notiﬁcation to the
sponsor. Physicians assess causality, and the expectedness
of any SAE thought to be related to a study drug, on the
web portal. Follow-up of SAEs continues until the event
has resolved or the patient has died. In this study,
primary and secondary study endpoints and their asso-
ciated symptoms and laboratory abnormalities are not
reported as Suspected Unexpected Serious Adverse
Drug Reactions. Further, adverse events that are neither
considered to be serious nor related to randomised
treatment are not reported.
Data analysis/statistical method
Sample size determination
Originally, the study was powered at 90% to exclude a 30%
poorer outcome on celecoxib compared with traditional
NSAIDs (HR=1.3) in the primary endpoint with a non-
inferiority analysis between the two treatment strategies.
However, owing to slower than expected recruitment and
lower than expected event rates, the trial steering commit-
tee made the decision to revise the power of the study to
80% and the non-inferiority limit to 1.4 in October 2011.
The statistical method to be used will involve a stratiﬁed
Cox proportional hazards model including the randomisa-
tion strata and the randomised treatment group as covari-
ates. Statistical signiﬁcance for the treatment differences
will be based on the Wald statistics and on two-sided 95%
CIs for the estimated HR comparing celecoxib to non-
selective NSAIDs. The original power calculations suggested
that, for an average duration of 2 years’ exposure to treat-
ment with a 30% non-inferiority limit and an
NSAID-exposed CV event rate of 2% per year, the study
would require 6841 subjects in each treatment group or
13 682 subjects in total and 611 patients with endpoints
(based on an intention-to-treat analysis). Since an
on-treatment analysis would result in reduced follow-up that
was difﬁcult to predict a priori, follow-up would be contin-
ued until 611 endpoints were identiﬁed in the per-protocol
population. Following the revision to the power calculation
made in 2011 (power 80%, non-inferiority limit 1.4), the
number of primary endpoints required to achieve adequate
power in the per-protocol population decreased to 277.
Primary analysis
A full Statistical Analysis Plan has been developed. The
ﬁrst analysis to be carried out will be a non-inferiority
analysis of the primary outcome based on the per-
protocol population (those subjects remaining on rando-
mised therapy) with a supporting non-inferiority analysis
based on the intention-to-treat population. A patient will
be considered to remain on the randomised therapy
until a period of 56 days following the last recorded pre-
scription of the medication allocated at randomisation
plus 28 calendar days.
Thus, the per-protocol analysis will censor subjects after:
▸ Discontinuation from original randomised therapy
(deﬁned as 84 days after the day of the last recorded
prescription);
▸ First primary study endpoint and
▸ Withdrawal of consent.
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If non-inferiority is demonstrated, a superiority ana-
lysis will be carried out based on the intention-to-treat
population.
Sensitivity analysis
A prospective sensitivity analysis will be performed,
adding a 90-day period to the per-protocol period (or end
of the study), to ensure that withdrawal or crossover is
not a presage of disease. This will be performed for
both primary and secondary endpoints.
Subgroup analyses and prognostic factors
Subgroup analyses will be conducted comparing cele-
coxib treatment with each of the individual non-selective
NSAID treatments allocated at randomisation. In add-
ition, subgroup analyses will be carried out for each of
the baseline covariates described below that are signiﬁ-
cant predictors of the primary endpoint in a Cox regres-
sion model including that variable alone plus the
stratiﬁcation categorical variable.
Baseline covariates include age, sex, baseline blood pres-
sure, baseline total cholesterol, high-density lipoprotein
and low-density lipoprotein cholesterols, body mass index,
smoking status, prior upper gastrointestinal bleed or per-
foration, history of peptic ulcer, Helicobacter pylori serology
status at baseline, diabetes, social deprivation category, use
of systemic (not inhaled) steroids at entry, indication for
NSAID, that is, rheumatoid arthritis or osteoarthritis diag-
nosis, randomised therapy and aspirin use.
Ethics and dissemination
Steering committee and independent data monitoring
committee
A steering committee oversees the conduct of the trial and
an independent data monitoring committee receives
unblinded data and has the power to recommend to the
steering committee modiﬁcations to the study conduct,
including early discontinuation of the study, based on a
risk/beneﬁt assessment of the study data.
Study sponsorship: monitoring, audit, quality control and
quality assurance
The University of Dundee is the study sponsor that
supervises the monitoring and undertakes the quality
assurance of the study.
Legal and ethical issues
The trial has been approved by the UK Multi-Centre
Research Ethics Committee (Reference number:
2006-005735-24) and the Medicines and Healthcare products
Regulatory Agency (Reference number: 07/MRE00/9). It is
also approved by the relevant authorities in Denmark and
the Netherlands. It is registered on ClinicalTrials.gov
(Reference number: NCT00447759). The trial is performed
in accordance with the protocol, International Conference
on Harmonization Good Clinical Practice guidelines,
ISPE Good Pharmacoepidemiology Practice guidance30 and
applicable local regulatory requirements and laws.
Dissemination
The results of the trial will be published in a peer-
reviewed scientiﬁc journal.
DISCUSSION
The methodology of SCOT differs from many traditional
trials in that follow-up is largely electronic, using
record-linkage techniques, and treatments are prescribed
within the usual healthcare setting. Such a design means
that the trial more closely mimics normal care. There have
been a number of publications of meta-analyses of the car-
diovascular risk-beneﬁt of celecoxib compared with
NSAIDs.31–33 Most of them showed that there was no
increase in cardiovascular risk in patients receiving cele-
coxib compared with traditional NSAIDs. Alongside the
current trial, SCOT, a more traditional trial is ongoing in
the USA—The Prospective Randomized Evaluation of
Celecoxib Integrated Safety versus Ibuprofen Or
Naproxen (PRECISION) trial.34 35 It is a randomised,
double-blind, parallel group study of cardiovascular safety
in osteoarthritis or rheumatoid arthritis patients with, or at
high risk of, cardiovascular disease comparing celecoxib
with naproxen and ibuprofen.
Traditional trials have good internal validity but less
external validity. A large streamlined safety trial is
expected to have good external validity. However, such a
trial becomes more observational with time and internal
validity becomes less reliable. The results of PRECISION
and SCOT are likely to be available by around 2014, and
we believe that the results will inform clinical practice in
a more reliable way than previous studies of the cardio-
vascular safety of NSAIDs. We believe that naturalistic
trials such as SCOT will be essential in shaping health-
care policy in the future.
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